

PTO  
JC574 U.S. PATENT OFFICE**LIST OF INFORMATION DISCLOSED BY APPLICANT**

(Use several sheets if necessary)

DOCKET NO.

SERIAL NO.

FILING DATE

1327/98  
0113

08/468,792

June 6, 1995

APPLICANT

GROUP

Robert D'Amato

1203

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME IF APPROPRIATE	CLASS	SUBCLASS	FILING DATE
	AA	5,605,914	02/25/97	Muller	514	339	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES      NO
	AB	WO 92/14455	09/03/92	PCT		
	AC					

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

AD	Fazal, N. et al., "Effect of blocking TNF-α on intracellular BCG (Bacillus Calmette Guerin) growth in human monocyte-derived macrophages", <i>FEMS Microbiology Immunology</i> , Vol. 105, pp. 337-346 (1992)
AE	Louzir, B. et al., "Érythroleucémie chez un patient ayant une maladie de Behcet et traité au long cours par thalidomide", <i>Annales De Medecine Interne</i> , Vol. 143, pp. 479-480, (1992)
AF	Hatfill, S.J., et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", <i>Leukemia Research</i> , Vol. 15, No. 2/3, pp.129-136 (1991)
AG	"Thalidomide: 20 Years On", <i>The Lancet</i> , Vol II, No. 8245, pp. 510-511 (1981)
AH	Revuz, J., "Actualité du Thalidomide", <i>Annales De Dermatologie</i> , Vol. 117, pp. 313-321 (1990)
AI	Vladutiu, A., "Another Chance for Thalidomide?", <i>The Lancet</i> , Vol. I, No. 7444, pp. 981-982 (1966)
AJ	Fabro, S. et al., "The Metabolism of Thalidomide: Some Biological Effects of Thalidomide and its Metabolites", <i>British Journal of Pharmacology and Chemotherapy</i> , Vol. 25, pp. 352-362 (1965)
AK	Fabro, S., "Biochemical Basis of Thalidomide Teratogenicity", <i>The Biochemical Basis of Chemical Teratogenesis</i> , Chapter 5, pp. 159-178 (1981)
AL	Eisenbud, L. et al., "Recurrent aphthous stomatitis of the Behcet's type: Successful treatment with thalidomide", <i>Oral Surgery, Oral Medicine, Oral Pathology</i> , Vol. 64, No. 3, pp. 289-292 (1987)
AM	Buckley, C. et al., "Pyoderma Gangrenosum with Severe Pharyngeal Ulceration", <i>Journal of the Royal Society of Medicine</i> , Vol. 83, pp. 290-291 (1990)
AN	Barnes, P.F. et al., "Tumor Necrosis Factor Production in Patients with Leprosy", <i>Infection and Immunity</i> , Vol. 60, No. 4, pp. 1441-1446 (1992)
AO	Barnhill, R.L. et al., "Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes", <i>Journal of the American Academy of Dermatology</i> , Vol. 11, No. 5, Part 1, pp. 814-819 (1984)
AP	Dicken, C.H., "Malignant Pyoderma", <i>Journal of the American Academy of Dermatology</i> , Vol. 13, No. 6, pp. 1021-1025 (1985)
AQ	O'Patey, et al., "Thalidomide et colite ulcéreuse dans la maladie de Behcet", <i>Gastroenterol Clinique Biologique</i> , Vol. 13, pp. 104-110 (1989)
AR	Naafs, B. et al., "Thalidomide Therapy", <i>International Journal of Dermatology</i> , Vol. 24, No. 2, pp. 131-134 (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

PTO  
U.S. PATENT AND TRADEMARK OFFICE  
JC574 U.S.

ATTY. DOCKET NO.

SERIAL NO.

FILING DATE

13-0113

08/468,792

June 6, 1995

APPLICANT

GROUP

D'Amato

1203

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

BA	Blaschke, V.G. et al., "Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere", <i>Arzneimittel Forschung Drug Research</i> , Vol. II, No. 10, 1640-1642 (1979)
BB	Kaplan, G. et al., "TNF $\alpha$ regulation of HIV1: biology and therapy", <i>Research in Immunology</i> , Vol. 145, No. 8-9, pp. 685-690 (1994)
BC	Bazzoli, A.S. et al., "The effects of thalidomide and two analogues on the regenerating forelimb of the newt", <i>Journal of Embryology and Experimental Morphology</i> , Vol. 41, pp. 125-135 (1977)
BD	Bernal, J.E. et al., "Cellular Immune Effects of Thalidomide in Actinic Prurigo", <i>International Journal of Dermatology</i> , Vol. 31, No. 8, pp. 599-600 (1992)
BE	Chaudhry, A. P. et al., "Effects of Prednisolone and Thalidomide on Induced Submandibular Gland Tumors in Hamsters", <i>Cancer Research</i> , Vol. 26, Part 1, pp. 1884--1886 (1996)
BF	Gershbein, L. L., "The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas", <i>Cancer Letters</i> , Vol. 60, pp. 129-133 (1991)
BG	Rainsford, K.D., "Disease-modifying antirheumatic and immunoregulatory agents", <i>Baillière's Clinical Rheumatology International Practice and Research</i> , Vol. 4, No. 3, pp. 405-433 (1990)
BH	Hamza, M., "Behcet's disease, palmoplantar pustulosis and HLA-B27 treatment with thalidomide", <i>Clinical and Experimental Rheumatology</i> , Vol. 8, No. 4, pp. 427 (1990)
BI	Ehrlich, G.E., "Behcet's Disease: Current Concepts", <i>Comprehensive Therapy</i> , Vol. 15, No. 1, pp. 27-30 (1989)
BJ	Barriere, H., "Sarcoides Cutanées. Traitement par la thalidomide", <i>La Presse Médicale</i> , Vol. 15, No. 12, pp. 963 (1983)
BK	Haffner, M.E., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", <i>Food and Drug Law Journal</i> , Vol. 48, pp. 205-211 (1993)
BL	Sherman, et al., "Thalidomide: A Twenty-Five Year Perspective", <i>Food Drug Cosmetic Law Journal</i> , Vol. 41, pp. 458-466 (1986)
BM	Burrows, N. P., "Diagnosis and Management of Systemic Lupus Erythematosus Thalidomide Modifies Disease", <i>British Medical Journal</i> , Vol. 307, No. 6909, pp. 939-940 (October 1993)
BN	Gutiérrez-Rodríguez, O. "Thalidomide A Promising New Treatment for Rheumatoid Arthritis", <i>Arthritis and Rheumatism</i> , Vol. 27, No. 10, pp. 1118-1121 (October 1984)
BO	Gutiérrez-Rodríguez, O., et al., "Treatment of Refractory Rheumatoid Arthritis - The Thalidomide Experience", <i>Journal of Rheumatology</i> , Vol. 16, No. 2, pp. 1158-163 (February 1989)
BP	Williams, K.M., "Enantiomers in Arthritic Disorders", <i>Pharmacology &amp; Therapeutics</i> , Vol. 46, No. 2, pp. 273-295 (1990)
BQ	De Cock, K. M., "Treatment of Ulcerative Colitis", letter, <i>British Medical Journal</i> , Vol. 1, p. 1356 (May 1979)
BR	Larsson, H., "Treatment of Severe Colitis in Behcet's Syndrome with Thalidomide (CG-217)", <i>Journal of Internal Medicine</i> , Vol. 228, No. 4, pp. 405-407 (October 1990) [letter]
BS	Waters, M.F. et al., "Treatment of Ulcerative Colitis with Thalidomide", <i>British Medical Journal</i> , Vol. 1, No. 6166, p. 792 (1979)
BT	Crain, E. et al., "The Effect of Thalidomide on Experimental Autoimmune Myasthenia Gravis", <i>Journal of Autoimmunity</i> , Vol. 2, pp. 197-202 (1989)
BU	Gunzler, V. "Thalidomide —A Therapy for the immunological Consequences of HIV Infection?", Vol. 30, No. 2, pp. 105-109 (October 1989)
BV	Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", <i>Pediatric Dermatology</i> , Vol. 10, No. 3, pp. 256-258 (September 1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

PTO  
U.S. PATENT AND TRADEMARK OFFICE  
JC574

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE
13-0113	08/468,792	June 6, 1995
APPLICANT Robert D'Amato		GROUP 1203
<b>OTHER REFERENCES</b> (Including Author, Title, Date, Pertinent Pages, Etc.)		
CA	Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", <i>Pediatric Dermatology</i> , Vol. 127, Supplement 40, pp. 67-68 (July 1992)	
CB	Field, E.O. et al., "Effect of Thalidomide on the Graft Versus Host Reaction", <i>Nature A Weekly Journal of Science</i> , Vol. 211, No. 5055, pp. 1308-1310 (September 1966)	
CC	Hellmann, K. et al., "Prolongation of Skin Homograft Survival by Thalidomide", <i>British Medical Journal</i> , Vol. II, pp. 687-689 (September 1965)	
CD	Heney, D. et al., "Thalidomide Treatment for Chronic Graft-Versus-Host Disease", <i>British Journal of Haematology</i> , Vol. 78, pp. 23-27 (1991)	
CE	Keenan, R. J. et al., "Immunosuppressive Properties of Thalidomide Inhibition of In Vitro Lymphocyte Proliferation Alone and in Combination with Cyclosporine or FK506 <sup>1</sup> ", <i>Transplantation</i> , Vol. 52, No. 5, pp. 908-910 (November 1991)	
CF	Lopez, J. et al., "Thalidomide as Therapy for Intestinal Chronic GVHD", <i>Bone Marrow Transplantation</i> , Vol. 11, No. 3, pp. 251-252 (1993)	
CG	Bach, A. et al., "Studies on the Possible Anti-Neoplastic Effect of Thalidomide", <i>ACTA Pathologica et Microbiologica Scandinavica</i> , Vol. 59, pp. 491-499 (1963)	
CH	Bahmer, F. A., "Therapy of Lymphocytic Infiltration", <i>Der Hautarzt</i> , Vol. 43, p. 663 (1992)	
CI	Gershbein L. L., "Effect of Various Agents on Liver Regeneration and Walker Tumor Growth in Partially Hepatectomized Rats", <i>Cancer Research</i> , Vol. 26 Part 1, pp. 1905-1908 (September 1966)	
CJ	Roe, F. J. et al., "Thalidomide and Neoplasia", <i>Nature</i> , Vol. 200, pp. 1016-1017 (December 1963)	
CK	Makonkawkeyoon, S. et al., "Thalidomide Inhibits the Replication of Human Immunodeficiency Virus Type 1", <i>Proceedings of the National Academy of Sciences</i> , Vol. 90, No. 13, pp. 5974-5978 (July 1993)	
CL	Meza, A.D. et al., "Managing the Gastrointestinal Complications of AIDS", <i>Drug Therapy</i> , Vol. 23, No. 11, pp. 74-83 (1993)	
CM	Gigliotti, G. R. et al., "Thalidomide: Treatment of Choice for Aphthous Ulcers in Patients Seropositive for Human Immunodeficiency Virus", <i>Journal of the American Academy of Dermatology</i> , Vol. 28, No. 2, Part 1, pp. 271-272 (February 1993)	
CN	Grinspan, D., "Significant Response of Oral Aphthosis to Thalidomide Treatment", <i>American Academy of Dermatology</i> , Vol. 12, No. 1, Part 1, pp. 85-90 (January 1985)	
CO	Kürkcüoglu, N. et al., "Thalidomide in the Treatment of Recurrent Necrotic Mucocutaneous Aphthae", <i>British Journal of Dermatology</i> , Vol. 112, No. 5, p. 632 (May 1985)	
CP	Powell, R.J. et al., "Investigation and Treatment of Orogenital Ulceration; Studies on a Possible Mode of Action of Thalidomide", <i>British Journal of Dermatology</i> , Vol. 113, Supplement 28, pp. 141-144 (1985)	
CQ	Revuz, J. et al., "Crossover Study of Thalidomide vs. Placebo in Severe Recurrent Aphthous Stomatitis", <i>Archives of Dermatology</i> , Vol. 126, No. 7, pp. 923-927 (July 1990)	
CR	Apt, W., "Effect of Thalidomide on the Course of Experimental Chagas' Disease", <i>BOI Chili Parasitol</i> , Vol. 20, No. 3, pp. 84-86 (September 1965)	
CS	Vicente, T. et al., "In Vitro Activity of Thalidomide against mycobacterium Avium Complex", <i>Archives of Internal Medicine</i> , Vol. 153, p. 534 (February 1993)	
CT	Eravelly, J. et al., "Thalidomide in Weber-Christian Disease", <i>Lancet</i> , Vol. 1, No. 8005, p. 251 (1977) [letter]	
CU	Lueprasitsakul, W. et al., "Effect of Thalidomide on the incidence of Iodine-Induced and Spontaneous Lymphocytic Thyroiditis and Spontaneous Diabetes Mellitus in the BB/W Rat", <i>Acta Endocrinologica</i> , Vol. 123, No. 1, pp. 79-83 (July 1990)	
CV	Misery, L. et al., "Remission of Langerhans Cell Histiocytosis with Thalidomide Treatment", <i>Clinical and Experimental Dermatology</i> , Vol. 18, No. 5, p. 487 (September 1993)	
CW	Rhoton, A.J., "Rle for Thalidomide in Primary Biliary Cirrhosis Treatment", <i>Gastroenterology</i> , Vol. 105, No. 3, p. 956 (September 1993)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

FORM PTO-1449, Adapted

**LIST OF INFORMATION DISCLOSED BY APPLICANT**  
*(Use several sheets if necessary)*

10 of 10

**DATE CONSIDERED**

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.